.Net Blogging Sales San Diego 
Xconomy
MARCH 27, 2019
San Diego-based Acadia (NASDAQ: ACAD ) announced in August that it had licensed the drug, trofinetide, for development and commercialization in North America as a treatment for Rett syndrome and other indications, including Fragile X syndrome. The results of the. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.
Xconomy
NOVEMBER 13, 2016
I started with a list of companies already screened by the San Diego Venture Group’s annual venture summit, and consulted with investors and startup mentors to refine the list. I widened my net this year. Such lists can be entirely relative, but I sought to adjust for the capricious effects of subjectivity.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Xconomy
JULY 7, 2016
Morristown, NJ-based Pernix (NASDAQ: PTX ) will cut 60 workers , mostly from its neurology sales staff, the company said today. In 2014, Pernix, then based in The Woodlands, TX, acquired San Diego-based Somaxon Pharmaceuticals. But filings also show the company’s net losses widening each year since 2012. million net loss.
Xconomy
AUGUST 8, 2016
It’s been less than a year since Needham, MA-based PTC (NASDAQ: PTC ) shelled out $65 million to acquire Vuforia, the augmented reality technology created by San Diego-based Qualcomm (NASDAQ: QCOM ). Vuforia’s headquarters has remained in San Diego, and Vuforia continues to operate four offices in Europe and Israel, Wright said.
Xconomy
DECEMBER 27, 2017
Speculation is rampant about a possible sea change in consumer attitudes toward the tech industry and its products—a shift that might affect sales, the regulatory environment, and other factors important to companies. We’ve just passed a year full of news about the role of technology companies in U.S.
Xconomy
AUGUST 19, 2016
And once in a while, a defender uses his or her face, inadvertently, to block a ball spiked over the net. —The FDA last summer approved two new cholesterol fighting drugs known as PCSK9 inhibitors, but so far the market has rejected them, resulting in paltry sales. Talk about sacrifice.
Xconomy
AUGUST 26, 2016
The deal also includes a $175 million deferred payment due in 2019 and $850 million in downstream payouts tied to regulatory and sales targets. Frank Vinluan has more on Novan, which relied on a variety of high net worth individuals, rather than venture firms, to get to this point.
Expert insights. Personalized for you.
97 
Let's personalize your content